The identification of these two compound heterozygous patients suggests that testing laboratories should be cautious while interpreting the c.36_37insGGAGTC and c.415C > T variants of NUDT15 in genetic testing of pediatric patients with ALL taking mercaptopurine or other related drugs, rather than only considering these genotypes. This evidence concerns the gene NUDT15 and acute lymphoblastic leukemia.